In 2016, Ambry led the largest study of its kind (20,000 cases) to give guidance on additional confirmatory testing: it found specific well-defined thresholds, reducing the chance of delivering a false positive patient report or one that misses real mutations (Mu et al., November 2016).ДЄmbry Genetics is both CAP-accredited and CLIA-approved. This is to ensure that the results healthcare providers receive are as accurate and informative as possible: the more accurate the reports, the more insight it can provide you, the Clinician, to treat your patients. Its ongoing participation in numerous research studies and collaborations is designed to help its scientists better assess clinical validity of gene-disease relationships. TumorNext HRD Info for clinicians The Ambry approachДЄmbry places significant value on implementing new lab processes designed to increase quality, and advancing technology across its field with innovative approaches. See also our TumorNext BRCA test Clinicians в–є Close tab The report will also indicate if mutations have been identified which are associated with the hereditary risk of developing other cancers, so that you and members of your family can take action to protect your health in future. Your clinician will receive a comprehensive analysis of the 11 genes in your DNA and particularly any mutations which indicate whether or not PARP inhibitor treatment could help you. Your sample will be analysed and a report will be generated, usually within three to four weeks of receipt of your sample in the laboratory. We will contact your pathologist directly and organise the collection of your sample and delivery to the laboratory. You will receive an email asking you to confirm that you have authorised ELG to be given a sample of your tumour tissue. Step 1: Purchase and permissionД«uy the test. This test is only available with authorisation from your clinician, who will receive your test results directly. You can discuss this with your clinician, or if you would like to talk to one of our experts about the test, call us on +44 (0) 1270 699021. The hereditary aspect of the TumorNext-HRD test analysis can also indicate if other members of your family have significantly increased risk of certain cancers вЂ“ so they too can arrange for appropriate monitoring or screening. This test can also indicate if you have a hereditary risk of developing other cancers вЂ“ and therefore what steps you need to take for further screening or monitoring. The TumorNext-HRD test analyses 11 genes in your DNA to give you and your clinician clear indications of whether targeted PARP inhibitor treatment will help you.

In effect, it causes tumour cells to die. It involves drugs which block an enzyme used by cancer cells to repair damage to their DNA caused by chemotherapy, but it doesnвЂ™t affect healthy cells. Most women who have ovarian cancer have particular gene mutations in their DNA вЂ“ specifically those in BRCA1 and BRCA2 genes.Д«ut that is not always the case, and if you have a different gene mutation, a new therapy that could help you is PARP inhibitor treatment.

Hrd test